文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

多中心研究网络 RIC-FRANCE 中，TNF 抑制剂在中轴型脊柱关节炎中的皮下注射保留率。

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network.

机构信息

LITEC, Université de Poitiers, CHU Poitiers, 86000, Poitiers, France.

Private Practice, Valenciennes, France.

出版信息

Sci Rep. 2024 Jan 16;14(1):1374. doi: 10.1038/s41598-024-52016-4.

DOI:10.1038/s41598-024-52016-4
PMID:38228719
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10791989/
Abstract

The objectives of our study were to assess retention rate, safety, and predictive factors for retention of subcutaneous (SC) TNF inhibitors (TNFi) (adalimumab (ADA), etanercept (ETN), golimumab (GOL), and certolizumab pegol (CZP)) in axial spondyloarthritis (axSpA) depending on the line of treatment in real-life conditions. A multicentre retrospective observational study was conducted including 552 patients fulfilling the ASAS criteria for axSpA followed in the RIC-France register who began SC-TNFi between 01/01/13 and 08/31/2018 for a total of 824 prescriptions. Taking all lines of treatment into account, GOL had a significantly higher retention rate compared with ADA, ETN, and CZP with a mean retention length of 59 months. As first-line bDMARDs, GOL had a significantly higher retention rate compared with ADA and ETN. ETN had the best retention rate when prescribed as at least 3rd bDMARD. Taking all lines of treatment into account, female sex, peripheral disease, BASDAI at initiation, and line of treatment were predictive factors for treatment cessation. Primary inefficiency was the most frequent reason for treatment cessation. In conclusion, GOL showed the highest retention rate in axSpA. Male sex, absence of peripheral disease, and early line of prescription were associated with better SC-TNFi retention in axSpA.

摘要

我们研究的目的是评估皮下（SC）TNF 抑制剂（TNFi）（阿达木单抗（ADA）、依那西普（ETN）、戈利木单抗（GOL）和培塞利珠单抗（CZP））在真实环境中治疗轴性脊柱关节炎（axSpA）时的保留率、安全性和保留的预测因素，这取决于治疗线数。一项多中心回顾性观察研究纳入了 552 名符合 axSpA ASAS 标准的患者，他们在 RIC-France 登记处接受治疗，这些患者于 2013 年 1 月 1 日至 2018 年 8 月 31 日之间开始接受 SC-TNFi 治疗，共开具了 824 张处方。考虑到所有的治疗线数，GOL 的保留率明显高于 ADA、ETN 和 CZP，平均保留时间为 59 个月。作为一线 bDMARD，GOL 的保留率明显高于 ADA 和 ETN。当 ETN 被处方为至少第 3 种 bDMARD 时，其保留率最佳。考虑到所有的治疗线数，女性、外周疾病、起始时 BASDAI 和治疗线数是治疗终止的预测因素。原发失效率是治疗终止的最常见原因。总之，GOL 在 axSpA 中显示出最高的保留率。在 axSpA 中，男性、无外周疾病和早期处方线数与更好的 SC-TNFi 保留率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/b282194cfa68/41598_2024_52016_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/2f4666f68737/41598_2024_52016_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/6803102d9505/41598_2024_52016_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/5b7eaba80d2e/41598_2024_52016_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/9da6f0933b23/41598_2024_52016_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/b282194cfa68/41598_2024_52016_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/2f4666f68737/41598_2024_52016_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/6803102d9505/41598_2024_52016_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/5b7eaba80d2e/41598_2024_52016_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/9da6f0933b23/41598_2024_52016_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84ab/10791989/b282194cfa68/41598_2024_52016_Fig5_HTML.jpg

相似文献

[1]
Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network.

Sci Rep. 2024-1-16

[2]
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.

Ann Rheum Dis. 2023-1

[3]
Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).

Int J Rheum Dis. 2018-11

[4]
High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.

Arthritis Res Ther. 2023-10-17

[5]
Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.

Rheumatology (Oxford). 2021-1-5

[6]
Tapering biologics in axial spondyloarthritis: A systematic literature review.

Int Immunopharmacol. 2022-11

[7]
Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.

Rheumatol Int. 2022-11

[8]
Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.

Rheumatology (Oxford). 2021-1-5

[9]
Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.

Ann Rheum Dis. 2015-2-9

[10]
Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.

Rheumatology (Oxford). 2018-4-1

引用本文的文献

[1]
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.

Rheumatol Int. 2024-10

[2]
Real-World Adherence and Drug Survival of Biologics among Patients with Ankylosing Spondylitis.

J Clin Med. 2024-7-31

本文引用的文献

[1]
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA).

RMD Open. 2023-3

[2]
Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study.

Front Med (Lausanne). 2022-10-6

[3]
Real-life golimumab persitence in patients with axial spondyloarthritis: post-hoc results of the prospective observational cohort study, GO-PRACTICE.

Clin Exp Rheumatol. 2022-7

[4]
Axial spondyloarthritis.

Ann Rheum Dis. 2021-12

[5]
Predicting Biologic Therapy Outcome of Patients With Spondyloarthritis: Joint Models for Longitudinal and Survival Analysis.

JMIR Med Inform. 2021-7-30

[6]
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study.

Front Med (Lausanne). 2021-5-26

[7]
Comparison of Men and Women With Axial Spondyloarthritis in the US-based Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

J Rheumatol. 2021-10

[8]
Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study.

Medicine (Baltimore). 2021-4-2

[9]
Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.

Rheumatology (Oxford). 2021-12-1

[10]
Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry.

BMC Rheumatol. 2020-11-15

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索